Treatment of Chronic Active Antibody-mediated Rejection With Bortezomib in Kidney Transplantation

Trial Profile

Treatment of Chronic Active Antibody-mediated Rejection With Bortezomib in Kidney Transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Immunoglobulins
  • Indications Transplant rejection
  • Focus Therapeutic Use
  • Acronyms TRIBUTE
  • Most Recent Events

    • 08 Apr 2015 Planned End Date changed from 1 Apr 2018 to 1 Oct 2018, as reported by ClinicalTrials.gov.
    • 08 Apr 2015 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2018, as reported by ClinicalTrials.gov.
    • 08 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top